Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study

Figures & data

Table 1. Review of all available incidence data on GCT-B

Article	Country	Type	Incidence per million inhabitants	Age median (range)	Percentage men
Liede et al. 2014 ^a	Sweden, Australia, Japan	Doctor-driven	1.03–1.33	20–40 (na)	na
Amelio et al. 2016 ^a	Sweden	Doctor-driven	1.3	34 (10–88)	48
Current study	The Netherlands	Nationwide pathology registry	1.66	35 (9–77)	42

na: not available. The study by Liede et al. does not report an exact median age, but only a median age group.

^a These studies probably also included patients with a giant cell tumor of the small bones of hands or feet and patients with central giant cell granulomas of the jaw.

Figure 1. Diagram showing inclusion and exclusion of all patients with GCT in the Netherlands between 2009 and 2013.

Figure 2. Crude incidence rates of GCT-B in the Netherlands with 95% confidence interval.

Figure 3. Age distribution of GCT-B in the Netherlands.

Table 2. Overview of incidence rates

	Crude incidence per million inhabitants per year (CI)	Age median (range)	Percentage men (CI)
GCT-B total	1.7 (1.4–1.9)	35 (9–77)	42 (34–50)
Long bones	1.3 (1.1–1.6)	35 (9–77)	41 (33–51)
Axial	0.35 (0.21–0.45)	38 (17–73)	46 (29–65)

Table 3. Frequencies of localizations of first GCT-B

Localization	Absolute frequency	Percentage (CI)
Femur	48	35 (27–43)
Tibia	25	18 (12–25)
Radius	14	10 (6–16)
Fibula	13	9 (6–15)
Spine	13	9 (6–15)
Ulna	5	4 (2–8)
Pelvis	5	4 (2–8)
Humerus	2	1 (0–5)
Mastoid	2	1 (0–5)
Patella	2	1 (0–5)
Scapula	2	1 (0–5)
Other *	3	2 (1–6)
Unknown	4	3 (1–7)
Total	138	100

^a Other: 4th rib, maxilla and petrous bone.

Table 4. Localization of recurrences

Localization	Absolute frequency	Percentage (CI)
Femur	10	30 (17–47)
Tibia	10	30 (17–47)
Spine	4	12 (5–27)
Radius	3	9 (3–24)
Humerus	2	6 (2–20)
Fibula	1	3 (1–15)
Ulna	1	3 (1–15)
Scapula	1	3 (1–15)
Pelvis	1	3 (1–15)
Total	33	100